Floatz logo

Serplulimab

MSI-H Solid Malignant Tumor

Shanghai Henlius Biotechmonoclonal_antibodyPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the MSI-H Solid Malignant Tumor cohort.

Asset / SponsorPhaseRating
Ipilimumab
Olivia Newton-John Cancer Research Institute
Phase 2CCC
Nivolumab
Olivia Newton-John Cancer Research Institute
Phase 2CCC
Pembrolizumab
Medicenna Therapeutics, Inc.
Phase 1/2CCC
Mdna11
Medicenna Therapeutics, Inc.
Phase 1/2CCC

Same molecule, other indications

Serplulimab is also rated in:

ImmunotherapyDormant
BB
Indicative ·
70 / 100
View asset →
non-small cell squamous lung carcinomaDormant
BB
Indicative ·
70 / 100
View asset →
small cell lung carcinomaDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →